Optimization of recombinant vaccinia-based ELISPOT assay

Area of Science:

• Immunology
• Cellular Biology
• Virology

Background:

• The ELISPOT assay is a sensitive method for measuring antigen-specific CD8 T cells.
• Recombinant vaccinia virus enhances antigen presentation in ELISPOT assays but causes high background and T cell toxicity.
• An improved method is needed to mitigate these limitations.

Purpose of the Study:

• To investigate the use of Cidofovir to inhibit vaccinia virus replication in ELISPOT assays.
• To evaluate the impact of Cidofovir on target cell function and antigen presentation.
• To determine optimal Cidofovir concentrations for enhancing assay sensitivity.

Main Methods:

• Recombinant vaccinia virus was used to infect target cells for antigen expression.
• Cidofovir was applied to inhibit vaccinia virus replication in infected target cells.
• ELISPOT assays were performed to assess T cell responses and antigen presentation efficiency.

Main Results:

• Cidofovir treatment inhibited vaccinia virus replication without compromising target cell viability.
• Cidofovir-treated cells exhibited enhanced presentation of internally processed antigens.
• Optimal Cidofovir concentrations were identified as 0.75-0.075 microg/ml.
• The methodology significantly increased the sensitivity of the ELISPOT assay.

Conclusions:

• Cidofovir treatment is a viable strategy to improve the ELISPOT assay for CD8 T cell detection.
• This approach reduces background noise and T cell toxicity associated with recombinant vaccinia virus.
• Optimized Cidofovir application enhances antigen presentation, leading to more sensitive T cell measurements.